eFT-508 is primarily utilized in the field of oncology as a targeted therapeutic agent. It functions as a selective inhibitor of MNK1 and MNK2 kinases, which are involved in the regulation of protein synthesis and play a role in cancer cell survival and proliferation. By inhibiting these kinases, eFT-508 disrupts the translation of oncogenic proteins, thereby hindering tumor growth and progression. This makes it a promising candidate for the treatment of various cancers, particularly those driven by aberrant protein synthesis. Additionally, eFT-508 is being explored for its potential to enhance the efficacy of other cancer therapies, such as immunotherapy, by modulating the tumor microenvironment and improving immune response against cancer cells. Its application is currently under investigation in clinical trials to evaluate its safety, tolerability, and effectiveness in patients with advanced solid tumors and hematologic malignancies.